IndraLab

Statements

Flecainide inhibits SCN5A. 8 / 17
9 | 8
reach
"Flecainide blocks the Nav1.5 channel in its inactivated state [ 8 ], therefore reducing the inward flow of sodium in the cell and slowing the physiological recovery of the Nav1.5 from the inactivated [MISSING/INVALID CREDENTIALS: limited to 200 char for Elsevier]"
31493514
reach
"The drug flecainide prevents arrhythmia in humans and mouse models of CPVT by blocking NaV1.5 and RYR2 channels."
34767014
reach
"Disease processes such as atrial fibrillation and left-sided versus right-sided heart failure affect cardiac cells within specific regions, although current pharmacotherapies for these may not specifically target the affected region-specific cell types, resulting in adverse outcomes (for example, the SCN5A blocker flecainide is used to treat atrial fibrillation but can induce ventricular arrhythmias )."
36950336
reach
"Flecainide blocks flow of the cardiac NaV1.5 sodium channel, slowing the upstroke and prolonging the cardiac action potential with minimal effect on repolarization."
20357296
reach
"Due to their distinct properties, several classes of well-known reference pharmacological agents, including hERG blockers such as cisapride ( Rampe, Roy, Dennis, & Brown, 1997 ) and dofetilide ( Kiehn[MISSING/INVALID CREDENTIALS: limited to 200 char for Elsevier]"
29330131
reach
"This conclusion is supported by the frequency dependence of wave inhibition by flecainide (Supplementary Figure S1); previous studies have demonstrated that flecainide inhibition of Nav1.5 is use/frequency dependent (Mestre et al., 2000)."
37124209
reach
"Flecainide further reduced theta ' max in the Scn5a +/- RV epicardium (from 0.05 (0.01) to 0.03 (0.028) ms -1; U = 18.0, P = 0.026, r = 0.54)."
23836691
reach
"Flecainide reduced the BCD ' in the Scn5a +/- RV epicardium (from 3.42 (0.77) to 2.66 (0.82); U = 20.0, P = 0.030, r = 0.48)."
23836691